ClinicaliQ Trial Snapshot
- A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Cough — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT07690059.
- Sponsor: Sensory Cloud, Inc.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a randomized placebo-controlled, parallel-arm study to determine the safety and efficacy of SC0032 in participants with RCC
Eligibility Snapshot
- : 1. Males and females between 18 and 80 years. 2. Capable of giving signed informed consent. 3. Diagnosed with RCC (including unexplained chronic cough) for at least 6 months. 4. At least 8 coughs per hour, 24-hour cough frequency during the 14-day Run-In Period. 5. Score ≥ 40 mm on cough severity VAS at Screening. 6. Normal FEV1/FVC ratio of greater than 70% at Screening 7. A negative test for COVID-19. 8. Women of child-bearing potential and men must agree to use a highly effective contraception method during the study and for at least 14 days after the last dose. 9. Willing to carry study-related equipment as required for the study (e.g. cough monitor, phone).
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.